<?xml version="1.0" encoding="UTF-8"?>
<p>Intravenous immunoglobulins (IVIg), monoclonal or polyclonal antibodies, and various other convalescent blood products have been developed to deal with infectious indispositions [
 <xref rid="RSOB200174C55" ref-type="bibr">55</xref>]. Despite this fact, they may not yield appropriate infection control and are quite difficult and expensive to produce. Therefore, due to the lack of effective vaccines and medications, CP therapy has been broadly implemented during various outbreaks as the first therapeutic alternative and sometimes as an experimental treatment or last resort [
 <xref rid="RSOB200174C45" ref-type="bibr">45</xref>].
</p>
